Literature DB >> 2841641

Gynecomastia as a presenting sign of fibrolamellar carcinoma of the liver.

J J McCloskey1, E L Germain-Lee, J A Perman, L P Plotnick, A H Janoski.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 2841641

Source DB:  PubMed          Journal:  Pediatrics        ISSN： 0031-4005            Impact factor:   7.124


× No keyword cloud information.
  16 in total

1.  A young woman with liver cancer.

Authors:  Celina S Ang; Richard K Do; Ali Shamseddine; Eileen M O'Reilly; Ali Haydar; Ashwaq Al-Olayan; Walid Faraj; Fouad Boulos; Mohamed Naghy; Dorothy Makanjoula; Hassan Farran; Hassan Sibai; David Wehbe; David P Kelsen; Ghassan K Abou-Alfa
Journal:  Gastrointest Cancer Res       Date:  2013-01

2.  Transcriptomic characterization of fibrolamellar hepatocellular carcinoma.

Authors:  Elana P Simon; Catherine A Freije; Benjamin A Farber; Gadi Lalazar; David G Darcy; Joshua N Honeyman; Rachel Chiaroni-Clarke; Brian D Dill; Henrik Molina; Umesh K Bhanot; Michael P La Quaglia; Brad R Rosenberg; Sanford M Simon
Journal:  Proc Natl Acad Sci U S A       Date:  2015-10-21       Impact factor: 11.205

Review 3.  Fibrolamellar hepatocellular carcinoma. Case reports and a review of the literature.

Authors:  S Saab; F Yao
Journal:  Dig Dis Sci       Date:  1996-10       Impact factor: 3.199

Review 4.  A framework for fibrolamellar carcinoma research and clinical trials.

Authors:  Timothy A Dinh; Alan F Utria; Kevin C Barry; Rosanna Ma; Ghassan K Abou-Alfa; John D Gordan; Elizabeth M Jaffee; John D Scott; Jessica Zucman-Rossi; Allison F O'Neill; Mark E Furth; Praveen Sethupathy
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2022-02-21       Impact factor: 73.082

5.  Typical fibrolamellar hepatocellular carcinoma in Japanese patients: report of two cases.

Authors:  J Tanaka; N Baba; S Arii; K Fujita; J Tamura; Y Kawakami; S Tsuji; M Imamura; H Yamabe; S Nakai
Journal:  Surg Today       Date:  1994       Impact factor: 2.549

6.  Clinicopathologic characteristics and survival outcomes of patients with fibrolamellar carcinoma: data from the fibrolamellar carcinoma consortium.

Authors:  Celina S Ang; R Katie Kelley; Michael A Choti; David P Cosgrove; Joanne F Chou; David Klimstra; Michael S Torbenson; Linda Ferrell; Timothy M Pawlik; Yuman Fong; Eileen M O'Reilly; Jennifer Ma; Joseph McGuire; Gandhi P Vallarapu; Ann Griffin; Francesco Stipa; Marinela Capanu; Ronald P Dematteo; Alan P Venook; Ghassan K Abou-Alfa
Journal:  Gastrointest Cancer Res       Date:  2013-01

7.  A Multicenter Randomized Three-Arm Phase II Study of (1) Everolimus, (2) Estrogen Deprivation Therapy (EDT) with Leuprolide + Letrozole, and (3) Everolimus + EDT in Patients with Unresectable Fibrolamellar Carcinoma.

Authors:  Imane El Dika; Robert J Mayer; Alan P Venook; Marinela Capanu; Michael P LaQuaglia; Rachel Kobos; Allison F O'Neill; Joanne F Chou; Michele Ly; Celina Ang; Eileen M O'Reilly; John D Gordan; Ghassan K Abou-Alfa
Journal:  Oncologist       Date:  2020-05-26

8.  Dynamic contrast-enhanced MR imaging of fibrolamellar hepatocellular carcinoma.

Authors:  K Corrigan; R C Semelka
Journal:  Abdom Imaging       Date:  1995 Mar-Apr

Review 9.  Fibrolamellar carcinoma: 2012 update.

Authors:  Michael Torbenson
Journal:  Scientifica (Cairo)       Date:  2012-09-23

10.  Hepatocellular Carcinoma, Fibrolamellar Variant: Diagnostic Pathologic Criteria and Molecular Pathology Update. A Primer.

Authors:  Consolato M Sergi
Journal:  Diagnostics (Basel)       Date:  2015-12-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.